Dr Reddy’s Laboratories reported a consolidated net profit of ₹1,347 crore for Q2 FY26, up 7% year-on-year from ₹1,255 crore. Revenue from operations grew 10% to ₹8,828 crore. The generic-pharma major cited strength in its Indian business and contribution from recent acquisitions, although margin pressures remain in the U.S. market. Management flagged that incremental growth will hinge on new launches, price erosion controls and cost optimisation. Analysts say the result is solid but expectations for a stronger margin uptick remain cautious.